Results 51 to 60 of about 54,330 (287)

Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators

American Journal of Hematology, EarlyView.
ABSTRACT Survival has improved substantially for patients with Hodgkin lymphoma (HL), but long‐term quality of life (QoL) remains incompletely understood. This was a Danish, nationwide, cross‐sectional study of QoL among persons with a diagnosis of HL matched 1:10 to general population comparators.
Sissel Johanne Godtfredsen, Joachim Baech, Mikkel Porsborg Andersen, Harman Yonis, Paw Jensen, Peter Kamper, Jacob H. Christensen, Rasmus Bo‐Dahl Sørensen, Martin Hutchings, Christian Torp‐Pedersen, Peter Sogaard, Henrik Boggild, Kristian H. Kragholm, Tarec C. El‐Galaly   +13 more
wiley   +1 more source

Mantle cell lymphoma presented as enteric intussusception and involved gallbladder

Journal of Cancer Research and Practice, 2017
Intussusception caused by a lymphomatous mass is extremely rare in adults. To date, only four cases of mantle cell lymphoma have intussusception as a treatment sequelae or complication.
Chih-Ching Chin, Junping Shiau, Wei-Ciao Wu   +2 more
doaj   +1 more source

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]

, 2011
Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V, Fanale MA, Hasenclever D, Katrina Farrell, Mike Leach, Orlandi E, Pamela Mckay, Savage KJ, Stein H   +8 more
core   +1 more source

Radioimmunotherapy in mantle cell lymphoma [PDF]

Best Practice & Research Clinical Haematology, 2012
Mantle cell lymphoma (MCL), though characterized by the chromosomal translocation t(11; 14) (q13; q32), is a heterogeneous disease. Often termed an aggressive lymphoma in the U.S., but included in indolent lymphoma trials in Europe, MCL is not curable with standard immuno-chemotherapy.
Alan P, Skarbnik, Mitchell R, Smith
openaire   +2 more sources

Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

American Journal of Hematology, EarlyView.
ABSTRACT CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies.
Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen‐kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J. Frank   +12 more
wiley   +1 more source

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Haematologica, 2017
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim   +11 more
doaj   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Pattern of calcification on CT and FDG-PET of a rare perineural mantle cell lymphoma: a potential of non-histological imaging marker [PDF]

, 2016
The presence of calcification in a particular FDG-avid soft tissue lesion may at times present uncertainty regarding the clinical course of the disease pathology. Calcific deposits are not specific for either benign or malignant aetiologies (Brant et al.,
Ahmad Saad, Fathinul Fikri, Nordin, Abdul Jalil, Shakher, Ramdave   +2 more
core  

PASD1: a promising target for the immunotherapy of haematological malignancies [PDF]

, 2013
In general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in ...
Denniss, Frances, Guinn, Barbara-Ann, Khan, Ghazala, Mills, Ken I., Pulford, Karen   +4 more
core   +3 more sources